| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
6-Aminonicotinamide (100 nM; 7 days) dramatically lowers AR+ in CRPC-derived C4-2 and 22Rv1 cell models, human AR+, and hormone-sensitive prostate cancer cell lines LNCaP and LAPC4. Basal and R1881-mediated ROS levels are increased by 6-aminonicotinamide (100 nM ± 10 nM R1881) for three days, suggesting that 6-aminonicotinamide is obstructing the cell's antioxidant defenses. In C4-2 cells, 6-aminonicotinamide can also raise ROS levels [3].
|
|---|---|
| ln Vivo |
6-Aminonicotinamide (20 mg/kg; intraperitoneally; stimulation time; days 1, 10, or 11 and 21) by itself caused a little but notable halt in tumor growth (4.3 +/- 0.8 days). Treatment with 6-Aminonicotinamide and radiation caused a tumor growth delay of 57.0+/-3.8 days in a CD8F1 breast tumor model [4].
|
| References |
|
| Additional Infomation |
6-Aminonicotinamide is a white crystalline solid. (NTP, 1992)
6-Aminonicotinamide is a monocarboxylic acid amide formed by the condensation of the carboxyl group and ammonia of 6-aminonicotinic acid. It is an inhibitor of the NADP+-dependent enzyme 6-phosphoglucuronide dehydrogenase, interfering with glycolysis, leading to ATP depletion, and synergistically killing cancer cells with DNA-crosslinking chemotherapeutic drugs such as cisplatin. It has teratogenic, antimetabolitic, and EC 1.1.1.44 (NADP+-dependent decarboxylphosphoglucuronide dehydrogenase) inhibitory effects. It is an aminopyridine compound, a primary amino compound, and a monocarboxylic acid amide. It is functionally related to 6-aminonicotinic acid. 6-Aminonicotinamide is a synthetic analog and a cytotoxic nicotinamide antagonist. 6-Aminonicotinamide forms aberrant NAD (a ubiquitous metabolic pathway coenzyme) analogs, thereby inhibiting the activity of NAD-dependent enzymes associated with ATP production. 6-Aminonicotinamide can impair cartilage formation, may have teratogenic effects, and enhance the effects of radiation therapy and cisplatin treatment (forming platinum-DNA complexes). (NCI04) A teratogenic vitamin antagonist. |
| Molecular Formula |
C6H7N3O
|
|---|---|
| Molecular Weight |
137.14
|
| Exact Mass |
137.058
|
| CAS # |
329-89-5
|
| PubChem CID |
9500
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
381.6±27.0 °C at 760 mmHg
|
| Melting Point |
245-248 °C(lit.)
|
| Flash Point |
184.6±23.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.644
|
| LogP |
0.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZLWYEPMDOUQDBW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7N3O/c7-5-2-1-4(3-9-5)6(8)10/h1-3H,(H2,7,9)(H2,8,10)
|
| Chemical Name |
6-aminopyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (729.18 mM)
H2O: 11.11 mg/mL (81.01 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 4 mg/mL (29.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2918 mL | 36.4591 mL | 72.9182 mL | |
| 5 mM | 1.4584 mL | 7.2918 mL | 14.5836 mL | |
| 10 mM | 0.7292 mL | 3.6459 mL | 7.2918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
